Elucigene has been developing in vitro diagnostics for oncology and reproductive health, including tests for cystic fibrosis screening and prenatal fetal aneuploidy screening.
The company said its higher revenues were due in part to international performance including continued penetration of Middle Eastern and Asian markets.
The company, which changed its name from Premaitha Health last month, saw a 73 percent increase in testing volumes during the first half of fiscal year 2018.
The placing and subscription shares that are part of the offering are expected to start trading on the AIM market of the London Stock Exchange later this month.
